Korro Bio, Inc. (KRRO)
| Market Cap | 176.41M -53.7% |
| Revenue (ttm) | 2.38M -62.1% |
| Net Income | -106.64M |
| EPS | -8.88 |
| Shares Out | 14.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 237,343 |
| Open | 12.04 |
| Previous Close | 12.05 |
| Day's Range | 11.28 - 12.49 |
| 52-Week Range | 5.20 - 42.93 |
| Beta | 2.36 |
| Analysts | Strong Buy |
| Price Target | 20.20 (+68.61%) |
| Est. Earnings | Nov 11, 2026 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d... [Read more]
Financial Performance
In 2025, Korro Bio's revenue was $6.39 million, an increase of 181.46% compared to the previous year's $2.27 million. Losses were -$117.26 million, 40.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price target is $20.2, which is an increase of 68.61% from the latest price.
News
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up ...
Korro Bio management to meet virtually with Oppenheimer
Virtual Meeting to be held on October 27 hosted by Oppenheimer.
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA...
Korro Bio management to meet with Piper Sandler
Meeting to be held in New York on October 19 hosted by Piper Sandler.
Korro Bio doses first cohort of participants in KRRO-121 trial
Korro Bio (KRRO) announced that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the company’s GalNAc-conjugated RNA-editing oligonucleotide in development...
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) p...
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to...
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to...
Korro Bio reports Q2 EPS ($1.07), consensus ($1.28)
“The second quarter reflected the compounding payoff of a strategy we’ve been executing over several years,” commented Ram Aiyar, Chief Executive Officer and President of Korro Bio (KRRO). “Adding KRR...
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation f...
Korro Bio Quarterly report: Q2 2026
Korro Bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
Korro Bio Earnings release: Q2 2026
Korro Bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Korro Bio initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Korro Bio (KRRO) with an Outperform rating and $21 price target
Korro to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to d...
Korro Bio selects KRRO-111 as development candidate
Korro Bio (KRRO) announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development. KRRO-111 is a proprietary GalNAc-conjugated oligonucleot...
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SE...
Korro Bio price target lowered to $15 from $20 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $15 from $20 and keeps a Buy rating on the shares. The firm cites the…
Korro Bio initiated with a Buy at Citi
Citi initiated coverage of Korro Bio (KRRO) with a Buy rating and $21 price target While the shares sold off 60% on the “modest” Phase 1/2 REWRITE data, the readout…
Korro Bio upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target
JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
As previously reported, JonesResearch analyst Catherine Novack upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target after the company reported Q1 results. While both Korro’s GalNAc-conju...
Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
“The first quarter marked significant scientific progress for Korro as we continued to advance our OPERA platform and build a pipeline of differentiated RNA editing medicines,” commented Ram Aiyar, Ch...
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic en...
Korro Bio Quarterly report: Q1 2026
Korro Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
Korro Bio Earnings release: Q1 2026
Korro Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Korro Bio Slides: Corporate presentation
Korro Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.